Merus NV (MRUS)
43.52
-1.50
(-3.33%)
USD |
NASDAQ |
May 20, 13:04
Merus Enterprise Value: 2.239B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 2.239B |
| May 16, 2024 | 2.305B |
| May 15, 2024 | 2.316B |
| May 14, 2024 | 2.290B |
| May 13, 2024 | 2.353B |
| May 10, 2024 | 2.275B |
| May 09, 2024 | 2.310B |
| May 08, 2024 | 2.426B |
| May 07, 2024 | 2.522B |
| May 06, 2024 | 2.441B |
| May 03, 2024 | 2.501B |
| May 02, 2024 | 2.450B |
| May 01, 2024 | 2.422B |
| April 30, 2024 | 2.298B |
| April 29, 2024 | 2.310B |
| April 26, 2024 | 2.306B |
| April 25, 2024 | 2.299B |
| April 24, 2024 | 2.126B |
| April 23, 2024 | 2.058B |
| April 22, 2024 | 2.036B |
| April 19, 2024 | 1.999B |
| April 18, 2024 | 2.038B |
| April 17, 2024 | 2.072B |
| April 16, 2024 | 2.028B |
| April 15, 2024 | 2.085B |
| Date | Value |
|---|---|
| April 12, 2024 | 2.119B |
| April 11, 2024 | 2.191B |
| April 10, 2024 | 2.112B |
| April 09, 2024 | 2.177B |
| April 08, 2024 | 2.245B |
| April 05, 2024 | 2.286B |
| April 04, 2024 | 2.277B |
| April 03, 2024 | 2.279B |
| April 02, 2024 | 2.315B |
| April 01, 2024 | 2.306B |
| March 31, 2024 | 2.305B |
| March 28, 2024 | 2.287B |
| March 27, 2024 | 2.270B |
| March 26, 2024 | 2.280B |
| March 25, 2024 | 2.271B |
| March 22, 2024 | 2.339B |
| March 21, 2024 | 2.393B |
| March 20, 2024 | 2.305B |
| March 19, 2024 | 2.285B |
| March 18, 2024 | 2.245B |
| March 15, 2024 | 2.220B |
| March 14, 2024 | 2.247B |
| March 13, 2024 | 2.289B |
| March 12, 2024 | 2.326B |
| March 11, 2024 | 2.429B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
89.13M
Minimum
Mar 18 2020
2.645B
Maximum
Mar 01 2024
640.96M
Average
537.09M
Median
Enterprise Value Benchmarks
| uniQure NV | -210.33M |
| ProQR Therapeutics NV | 52.22M |
| argenx SE | 18.56B |
| Pharming Group | 559.22M |
| Pharvaris NV | 697.40M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -34.46M |
| Revenue (Quarterly) | 7.889M |
| Total Expenses (Quarterly) | 54.70M |
| EPS Diluted (Quarterly) | -0.59 |
| Profit Margin (Quarterly) | -436.8% |
| Earnings Yield | -6.36% |
| Normalized Earnings Yield | -6.471 |